questionsmedicales.fr
Actions chimiques et utilisations
Actions pharmacologiques
Mécanismes moléculaires de l'action pharmacologique
Antienzymes
Antienzymes : Questions médicales fréquentes
Termes MeSH sélectionnés :
Mendelian Randomization Analysis
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Antienzymes : Questions médicales les plus fréquentes",
"headline": "Antienzymes : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Antienzymes : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-07-26",
"dateModified": "2025-04-22",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Antienzymes"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Mécanismes moléculaires de l'action pharmacologique",
"url": "https://questionsmedicales.fr/mesh/D045504",
"about": {
"@type": "MedicalCondition",
"name": "Mécanismes moléculaires de l'action pharmacologique",
"code": {
"@type": "MedicalCode",
"code": "D045504",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs des protéines activatrices de la 5-lipoxygénase",
"alternateName": "5-Lipoxygenase-Activating Protein Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D058946",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs des protéines activatrices de la 5-lipoxygénase",
"code": {
"@type": "MedicalCode",
"code": "D058946",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.086"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de l'acétaldéhyde déshydrogénase",
"alternateName": "Acetaldehyde Dehydrogenase Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D065086",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de l'acétaldéhyde déshydrogénase",
"code": {
"@type": "MedicalCode",
"code": "D065086",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.089"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de l'adénosine désaminase",
"alternateName": "Adenosine Deaminase Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D058892",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de l'adénosine désaminase",
"code": {
"@type": "MedicalCode",
"code": "D058892",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.092"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs des adénylate cyclases",
"alternateName": "Adenylyl Cyclase Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D000067956",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs des adénylate cyclases",
"code": {
"@type": "MedicalCode",
"code": "D000067956",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.108"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de la calcineurine",
"alternateName": "Calcineurin Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D065095",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de la calcineurine",
"code": {
"@type": "MedicalCode",
"code": "D065095",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.174"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de l'anhydrase carbonique",
"alternateName": "Carbonic Anhydrase Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D002257",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de l'anhydrase carbonique",
"code": {
"@type": "MedicalCode",
"code": "D002257",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.200"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs et modulateurs de la gamma-secrétase",
"alternateName": "Gamma Secretase Inhibitors and Modulators",
"url": "https://questionsmedicales.fr/mesh/D000091062",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs et modulateurs de la gamma-secrétase",
"code": {
"@type": "MedicalCode",
"code": "D000091062",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.315"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs des enzymes du cytochrome P-450",
"alternateName": "Cytochrome P-450 Enzyme Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D065607",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs des enzymes du cytochrome P-450",
"code": {
"@type": "MedicalCode",
"code": "D065607",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.335"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs du cytochrome P-450 CYP1A2",
"alternateName": "Cytochrome P-450 CYP1A2 Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D065609",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs du cytochrome P-450 CYP1A2",
"code": {
"@type": "MedicalCode",
"code": "D065609",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.335.120"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs du cytochrome P-450 CYP2B6",
"alternateName": "Cytochrome P-450 CYP2B6 Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D065686",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs du cytochrome P-450 CYP2B6",
"code": {
"@type": "MedicalCode",
"code": "D065686",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.335.260"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs du cytochrome P-450 CYP2C8",
"alternateName": "Cytochrome P-450 CYP2C8 Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D065687",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs du cytochrome P-450 CYP2C8",
"code": {
"@type": "MedicalCode",
"code": "D065687",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.335.308"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs du cytochrome P-450 CYP2C19",
"alternateName": "Cytochrome P-450 CYP2C19 Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D065689",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs du cytochrome P-450 CYP2C19",
"code": {
"@type": "MedicalCode",
"code": "D065689",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.335.319"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs du cytochrome P-450 CYP2C9",
"alternateName": "Cytochrome P-450 CYP2C9 Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D065688",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs du cytochrome P-450 CYP2C9",
"code": {
"@type": "MedicalCode",
"code": "D065688",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.335.329"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs du cytochrome P-450 CYP2D6",
"alternateName": "Cytochrome P-450 CYP2D6 Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D065690",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs du cytochrome P-450 CYP2D6",
"code": {
"@type": "MedicalCode",
"code": "D065690",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.335.368"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs du cytochrome P-450 CYP2E1",
"alternateName": "Cytochrome P-450 CYP2E1 Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D065691",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs du cytochrome P-450 CYP2E1",
"code": {
"@type": "MedicalCode",
"code": "D065691",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.335.421"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs du cytochrome P-450 CYP3A",
"alternateName": "Cytochrome P-450 CYP3A Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D065692",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs du cytochrome P-450 CYP3A",
"code": {
"@type": "MedicalCode",
"code": "D065692",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.335.503"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Antifoliques",
"alternateName": "Folic Acid Antagonists",
"url": "https://questionsmedicales.fr/mesh/D005493",
"about": {
"@type": "MedicalCondition",
"name": "Antifoliques",
"code": {
"@type": "MedicalCode",
"code": "D005493",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.350"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de désacétylase d'histone",
"alternateName": "Histone Deacetylase Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D056572",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de désacétylase d'histone",
"code": {
"@type": "MedicalCode",
"code": "D056572",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.360"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de l'intégrase",
"alternateName": "Integrase Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D019429",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de l'intégrase",
"code": {
"@type": "MedicalCode",
"code": "D019429",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.375"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de la lipoxygénase",
"alternateName": "Lipoxygenase Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D016859",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de la lipoxygénase",
"code": {
"@type": "MedicalCode",
"code": "D016859",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.480"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de la monoamine oxydase",
"alternateName": "Monoamine Oxidase Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D008996",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de la monoamine oxydase",
"code": {
"@type": "MedicalCode",
"code": "D008996",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.616"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de la synthèse d'acide nucléique",
"alternateName": "Nucleic Acid Synthesis Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D019384",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de la synthèse d'acide nucléique",
"code": {
"@type": "MedicalCode",
"code": "D019384",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.675"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de l'ornithine décarboxylase",
"alternateName": "Ornithine Decarboxylase Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D065108",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de l'ornithine décarboxylase",
"code": {
"@type": "MedicalCode",
"code": "D065108",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.705"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de la phosphodiestérase",
"alternateName": "Phosphodiesterase Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D010726",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de la phosphodiestérase",
"code": {
"@type": "MedicalCode",
"code": "D010726",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.735"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de la phosphodiestérase-3",
"alternateName": "Phosphodiesterase 3 Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D058987",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de la phosphodiestérase-3",
"code": {
"@type": "MedicalCode",
"code": "D058987",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.735.249"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de la phosphodiestérase-4",
"alternateName": "Phosphodiesterase 4 Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D058988",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de la phosphodiestérase-4",
"code": {
"@type": "MedicalCode",
"code": "D058988",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.735.374"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de la phosphodiestérase-5",
"alternateName": "Phosphodiesterase 5 Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D058986",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de la phosphodiestérase-5",
"code": {
"@type": "MedicalCode",
"code": "D058986",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.735.500"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs des phosphoinositide-3 kinases",
"alternateName": "Phosphoinositide-3 Kinase Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D000081082",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs des phosphoinositide-3 kinases",
"code": {
"@type": "MedicalCode",
"code": "D000081082",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.736"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de la phospholipase A2",
"alternateName": "Phospholipase A2 Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D064801",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de la phospholipase A2",
"code": {
"@type": "MedicalCode",
"code": "D064801",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.737"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de prolyle hydroxylases",
"alternateName": "Prolyl-Hydroxylase Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D064800",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de prolyle hydroxylases",
"code": {
"@type": "MedicalCode",
"code": "D064800",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.740"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de protéases",
"alternateName": "Protease Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D011480",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de protéases",
"code": {
"@type": "MedicalCode",
"code": "D011480",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.745"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de l'enzyme de conversion de l'angiotensine",
"alternateName": "Angiotensin-Converting Enzyme Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D000806",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de l'enzyme de conversion de l'angiotensine",
"code": {
"@type": "MedicalCode",
"code": "D000806",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.745.085"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs des vasopeptidases",
"alternateName": "Vasopeptidase Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D000075563",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs des vasopeptidases",
"code": {
"@type": "MedicalCode",
"code": "D000075563",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.745.085.500"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs des vasopeptidases",
"alternateName": "Vasopeptidase Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D000075563",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs des vasopeptidases",
"code": {
"@type": "MedicalCode",
"code": "D000075563",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.745.085.500"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de la cystéine protéinase",
"alternateName": "Cysteine Proteinase Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D015853",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de la cystéine protéinase",
"code": {
"@type": "MedicalCode",
"code": "D015853",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.745.325"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs des caspases",
"alternateName": "Caspase Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D061945",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs des caspases",
"code": {
"@type": "MedicalCode",
"code": "D061945",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.745.325.500"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs des caspases",
"alternateName": "Caspase Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D061945",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs des caspases",
"code": {
"@type": "MedicalCode",
"code": "D061945",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.745.325.500"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de métalloprotéinases matricielles",
"alternateName": "Matrix Metalloproteinase Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D061965",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de métalloprotéinases matricielles",
"code": {
"@type": "MedicalCode",
"code": "D061965",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.745.610"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs du protéasome",
"alternateName": "Proteasome Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D061988",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs du protéasome",
"code": {
"@type": "MedicalCode",
"code": "D061988",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.745.705"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de la rénine",
"alternateName": "Renin Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D000092502",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de la rénine",
"code": {
"@type": "MedicalCode",
"code": "D000092502",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.745.753"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de la sérine protéinase",
"alternateName": "Serine Proteinase Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D015842",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de la sérine protéinase",
"code": {
"@type": "MedicalCode",
"code": "D015842",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.745.800"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de serine peptidase de type Kazal",
"alternateName": "Serine Peptidase Inhibitors, Kazal Type",
"url": "https://questionsmedicales.fr/mesh/D000074162",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de serine peptidase de type Kazal",
"code": {
"@type": "MedicalCode",
"code": "D000074162",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.745.800.562"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Serpines",
"alternateName": "Serpins",
"url": "https://questionsmedicales.fr/mesh/D015843",
"about": {
"@type": "MedicalCondition",
"name": "Serpines",
"code": {
"@type": "MedicalCode",
"code": "D015843",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.745.800.675"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs trypsiques",
"alternateName": "Trypsin Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D014361",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs trypsiques",
"code": {
"@type": "MedicalCode",
"code": "D014361",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.745.800.900"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de serine peptidase de type Kazal",
"alternateName": "Serine Peptidase Inhibitors, Kazal Type",
"url": "https://questionsmedicales.fr/mesh/D000074162",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de serine peptidase de type Kazal",
"code": {
"@type": "MedicalCode",
"code": "D000074162",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.745.800.562"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Serpines",
"alternateName": "Serpins",
"url": "https://questionsmedicales.fr/mesh/D015843",
"about": {
"@type": "MedicalCondition",
"name": "Serpines",
"code": {
"@type": "MedicalCode",
"code": "D015843",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.745.800.675"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs trypsiques",
"alternateName": "Trypsin Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D014361",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs trypsiques",
"code": {
"@type": "MedicalCode",
"code": "D014361",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.745.800.900"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de protéines kinases",
"alternateName": "Protein Kinase Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D047428",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de protéines kinases",
"code": {
"@type": "MedicalCode",
"code": "D047428",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.755"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs des Janus kinases",
"alternateName": "Janus Kinase Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D000075242",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs des Janus kinases",
"code": {
"@type": "MedicalCode",
"code": "D000075242",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.755.500"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de protéine-tyrosine kinase",
"alternateName": "Tyrosine Protein Kinase Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D000092004",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de protéine-tyrosine kinase",
"code": {
"@type": "MedicalCode",
"code": "D000092004",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.755.875"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de la synthèse protéique",
"alternateName": "Protein Synthesis Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D011500",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de la synthèse protéique",
"code": {
"@type": "MedicalCode",
"code": "D011500",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.760"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de la pompe à protons",
"alternateName": "Proton Pump Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D054328",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de la pompe à protons",
"code": {
"@type": "MedicalCode",
"code": "D054328",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.848"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Agents découplants",
"alternateName": "Uncoupling Agents",
"url": "https://questionsmedicales.fr/mesh/D014475",
"about": {
"@type": "MedicalCondition",
"name": "Agents découplants",
"code": {
"@type": "MedicalCode",
"code": "D014475",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.936"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Antienzymes",
"alternateName": "Enzyme Inhibitors",
"code": {
"@type": "MedicalCode",
"code": "D004791",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Xiaoxi Liu",
"url": "https://questionsmedicales.fr/author/Xiaoxi%20Liu",
"affiliation": {
"@type": "Organization",
"name": "Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA, USA."
}
},
{
"@type": "Person",
"name": "Robert S Magin",
"url": "https://questionsmedicales.fr/author/Robert%20S%20Magin",
"affiliation": {
"@type": "Organization",
"name": "Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA, USA."
}
},
{
"@type": "Person",
"name": "Nathan J Schauer",
"url": "https://questionsmedicales.fr/author/Nathan%20J%20Schauer",
"affiliation": {
"@type": "Organization",
"name": "Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA, USA."
}
},
{
"@type": "Person",
"name": "Sara J Buhrlage",
"url": "https://questionsmedicales.fr/author/Sara%20J%20Buhrlage",
"affiliation": {
"@type": "Organization",
"name": "Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA, USA. saraj_buhrlage@dfci.harvard.edu."
}
},
{
"@type": "Person",
"name": "R Gentry Wilkerson",
"url": "https://questionsmedicales.fr/author/R%20Gentry%20Wilkerson",
"affiliation": {
"@type": "Organization",
"name": "Department of Emergency Medicine, University of Maryland School of Medicine, 110 South Paca Street, 6th Floor, Suite 200, Baltimore, MD 21201, USA. Electronic address: gwilkerson@som.umaryland.edu."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Immunophenotypic variations in syphilis: insights from Mendelian randomization analysis.",
"datePublished": "2024-04-17",
"url": "https://questionsmedicales.fr/article/38694502",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3389/fimmu.2024.1380720"
}
},
{
"@type": "ScholarlyArticle",
"name": "Mendelian Randomization Analysis of the Association of SOCS3 Methylation with Abdominal Obesity.",
"datePublished": "2022-09-16",
"url": "https://questionsmedicales.fr/article/36145200",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/nu14183824"
}
},
{
"@type": "ScholarlyArticle",
"name": "Sleep behaviors and Parkinson's disease: A bidirectional Mendelian randomization analysis.",
"datePublished": "2023-01-03",
"url": "https://questionsmedicales.fr/article/36608706",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.bbr.2022.114281"
}
},
{
"@type": "ScholarlyArticle",
"name": "Association between various cathepsins and uterine leiomyoma: A Mendelian randomization analysis.",
"datePublished": "2024-09-12",
"url": "https://questionsmedicales.fr/article/39264885",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1371/journal.pone.0310292"
}
},
{
"@type": "ScholarlyArticle",
"name": "Childhood obesity and hypertension in pregnancy: a two-sample Mendelian randomization analysis.",
"datePublished": "2023-04-19",
"url": "https://questionsmedicales.fr/article/37074353",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1097/HJH.0000000000003442"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Actions chimiques et utilisations",
"item": "https://questionsmedicales.fr/mesh/D020164"
},
{
"@type": "ListItem",
"position": 3,
"name": "Actions pharmacologiques",
"item": "https://questionsmedicales.fr/mesh/D020228"
},
{
"@type": "ListItem",
"position": 4,
"name": "Mécanismes moléculaires de l'action pharmacologique",
"item": "https://questionsmedicales.fr/mesh/D045504"
},
{
"@type": "ListItem",
"position": 5,
"name": "Antienzymes",
"item": "https://questionsmedicales.fr/mesh/D004791"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Antienzymes - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Antienzymes",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-13",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Antienzymes",
"description": "Comment diagnostiquer une inhibition enzymatique ?\nQuels symptômes indiquent une inhibition enzymatique ?\nQuels tests sont utilisés pour détecter les antienzymes ?\nPeut-on utiliser l'imagerie pour diagnostiquer ?\nQuels marqueurs biochimiques sont associés aux antienzymes ?",
"url": "https://questionsmedicales.fr/mesh/D004791?mesh_terms=Mendelian+Randomization+Analysis&page=2#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Antienzymes",
"description": "Quels sont les symptômes d'une inhibition enzymatique ?\nL'inhibition enzymatique peut-elle causer des douleurs ?\nY a-t-il des symptômes spécifiques selon l'enzyme inhibée ?\nLes symptômes sont-ils toujours présents ?\nComment les symptômes évoluent-ils avec le temps ?",
"url": "https://questionsmedicales.fr/mesh/D004791?mesh_terms=Mendelian+Randomization+Analysis&page=2#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Antienzymes",
"description": "Comment prévenir l'inhibition enzymatique ?\nLes vaccinations peuvent-elles prévenir des inhibitions enzymatiques ?\nY a-t-il des habitudes de vie à adopter ?\nLes contrôles médicaux réguliers sont-ils importants ?\nL'éducation sur les médicaments est-elle nécessaire ?",
"url": "https://questionsmedicales.fr/mesh/D004791?mesh_terms=Mendelian+Randomization+Analysis&page=2#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Antienzymes",
"description": "Quels traitements existent pour l'inhibition enzymatique ?\nLes antienzymes sont-ils utilisés en chimiothérapie ?\nComment les inhibiteurs enzymatiques sont-ils administrés ?\nY a-t-il des effets secondaires aux antienzymes ?\nLes traitements sont-ils personnalisés ?",
"url": "https://questionsmedicales.fr/mesh/D004791?mesh_terms=Mendelian+Randomization+Analysis&page=2#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Antienzymes",
"description": "Quelles complications peuvent survenir avec l'inhibition enzymatique ?\nL'inhibition enzymatique peut-elle entraîner des maladies chroniques ?\nY a-t-il des risques de surdosage avec les antienzymes ?\nComment gérer les complications liées aux antienzymes ?\nLes complications sont-elles réversibles ?",
"url": "https://questionsmedicales.fr/mesh/D004791?mesh_terms=Mendelian+Randomization+Analysis&page=2#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Antienzymes",
"description": "Quels sont les facteurs de risque d'inhibition enzymatique ?\nL'âge influence-t-il le risque d'inhibition enzymatique ?\nLes maladies auto-immunes sont-elles un facteur de risque ?\nLe mode de vie affecte-t-il le risque ?\nLes médicaments peuvent-ils être des facteurs de risque ?",
"url": "https://questionsmedicales.fr/mesh/D004791?mesh_terms=Mendelian+Randomization+Analysis&page=2#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une inhibition enzymatique ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests sanguins et des analyses biochimiques évaluent l'activité enzymatique."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent une inhibition enzymatique ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme la fatigue, la douleur abdominale ou des troubles digestifs peuvent apparaître."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour détecter les antienzymes ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests d'activité enzymatique et les dosages spécifiques d'anticorps sont courants."
}
},
{
"@type": "Question",
"name": "Peut-on utiliser l'imagerie pour diagnostiquer ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'imagerie peut aider à évaluer les organes affectés, mais n'est pas spécifique aux antienzymes."
}
},
{
"@type": "Question",
"name": "Quels marqueurs biochimiques sont associés aux antienzymes ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les niveaux d'enzymes spécifiques dans le sang peuvent indiquer une inhibition enzymatique."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'une inhibition enzymatique ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent douleurs abdominales, nausées, et troubles métaboliques."
}
},
{
"@type": "Question",
"name": "L'inhibition enzymatique peut-elle causer des douleurs ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut entraîner des douleurs dues à des troubles digestifs ou métaboliques."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes spécifiques selon l'enzyme inhibée ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes varient selon l'enzyme affectée, comme la lactase ou la lipase."
}
},
{
"@type": "Question",
"name": "Les symptômes sont-ils toujours présents ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, certains patients peuvent être asymptomatiques malgré une inhibition enzymatique."
}
},
{
"@type": "Question",
"name": "Comment les symptômes évoluent-ils avec le temps ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes peuvent s'aggraver si l'inhibition persiste sans traitement approprié."
}
},
{
"@type": "Question",
"name": "Comment prévenir l'inhibition enzymatique ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée et l'évitement de substances toxiques peuvent aider."
}
},
{
"@type": "Question",
"name": "Les vaccinations peuvent-elles prévenir des inhibitions enzymatiques ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines vaccinations peuvent prévenir des infections qui causent des inhibitions enzymatiques."
}
},
{
"@type": "Question",
"name": "Y a-t-il des habitudes de vie à adopter ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, éviter l'alcool et le tabac peut réduire le risque d'inhibition enzymatique."
}
},
{
"@type": "Question",
"name": "Les contrôles médicaux réguliers sont-ils importants ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des contrôles réguliers permettent de détecter précocement des problèmes enzymatiques."
}
},
{
"@type": "Question",
"name": "L'éducation sur les médicaments est-elle nécessaire ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, comprendre les effets des médicaments aide à prévenir les inhibitions enzymatiques."
}
},
{
"@type": "Question",
"name": "Quels traitements existent pour l'inhibition enzymatique ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent des médicaments spécifiques et des modifications diététiques."
}
},
{
"@type": "Question",
"name": "Les antienzymes sont-ils utilisés en chimiothérapie ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains antienzymes sont utilisés pour cibler des enzymes dans les cellules cancéreuses."
}
},
{
"@type": "Question",
"name": "Comment les inhibiteurs enzymatiques sont-ils administrés ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils peuvent être administrés par voie orale, intraveineuse ou topique selon le cas."
}
},
{
"@type": "Question",
"name": "Y a-t-il des effets secondaires aux antienzymes ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des effets secondaires comme des nausées, des éruptions cutanées ou des douleurs peuvent survenir."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils personnalisés ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le traitement est souvent adapté en fonction de la cause et de la gravité de l'inhibition."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec l'inhibition enzymatique ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications comme des troubles métaboliques ou des maladies organiques peuvent survenir."
}
},
{
"@type": "Question",
"name": "L'inhibition enzymatique peut-elle entraîner des maladies chroniques ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une inhibition prolongée peut contribuer à des maladies chroniques comme le diabète."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques de surdosage avec les antienzymes ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un surdosage peut entraîner des effets indésirables graves et des complications."
}
},
{
"@type": "Question",
"name": "Comment gérer les complications liées aux antienzymes ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gestion implique un suivi médical régulier et des ajustements de traitement."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être réversibles avec un traitement approprié et rapide."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque d'inhibition enzymatique ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent des antécédents familiaux, des maladies héréditaires et des habitudes alimentaires."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il le risque d'inhibition enzymatique ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le risque augmente souvent avec l'âge en raison de la dégradation enzymatique naturelle."
}
},
{
"@type": "Question",
"name": "Les maladies auto-immunes sont-elles un facteur de risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines maladies auto-immunes peuvent augmenter le risque d'inhibition enzymatique."
}
},
{
"@type": "Question",
"name": "Le mode de vie affecte-t-il le risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un mode de vie sédentaire et une mauvaise alimentation augmentent le risque."
}
},
{
"@type": "Question",
"name": "Les médicaments peuvent-ils être des facteurs de risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains médicaments peuvent interférer avec l'activité enzymatique et augmenter le risque."
}
}
]
}
]
}
Infection with...
Utilizing summary data from genome-wide association studies, we employed a two-sample Mendelian randomization method to investigate the association between 731 immunophenotypes and syphilis. Syphilis ...
Our findings revealed that 33, 36, and 27 immunophenotypes of peripheral blood were associated with syphilis (regardless of disease stage), early syphilis and late syphilis, respectively. Subsequent a...
Multiple immunophenotypes demonstrated associations with syphilis, showcasing substantial disparities between the early and late stages of the disease. These findings hold promise for informing immuno...
This study was conducted to evaluate the potential causality association of SOCS3 methylation with abdominal obesity using Mendelian randomization. A case-control study, including 1064 participants, w...
Whether the quantity and quality of sleep are the risk factors for the development of Parkinson's disease remains unclear though it has now been confirmed that the quality of sleep among patients with...
The summary-level data collected from the published genome-wide association studies was used for analysis. Besides, the genetic relationships between different sleep-related phenotypes, including self...
In general, there was insufficient evidence to support the causal effect of sleep-related phenotypes on risk (N cases/controls = 33,674/449,056) and age at the onset (N cases = 28,568) of Parkinson's ...
The results of this study suggest that insomnia-associated single nucleotide polymorphisms are more frequent in later onset Parkinson's disease patients compared to earlier onset patients. However, gi...
Emerging evidence suggests a tentative association between cathepsins and uterine leiomyoma (UL). Previous investigations have predominantly focused on the role of cathepsins in the metastasis and col...
The causal relationship between childhood obesity and hypertension in pregnancy remains unclear. To examine the causal association between childhood obesity and hypertension in pregnancy, two-sample M...
Single-nucleotide polymorphisms (SNPs) associated with childhood obesity were obtained from a published genome-wide association study (GWAS) of 13 848 European individuals. Summary-level data for hype...
Genetically determined childhood obesity significantly affects hypertension in pregnancy by IVW [odds ratio (OR) = 1.161, 95% confidence interval (CI) 1.086-1.039; P = 9.92 × 10 -6 ] and weighted medi...
A causal effect between genetically predicted childhood obesity and the risk of hypertension in pregnancy was identified. The prevention of hypertension in pregnancy should be promoted in populations ...
This analysis assessed the putative causal association between genetically predicted percent body fat and areal bone mineral density (aBMD) and, more specifically, the association between genetically ...
Mendelian randomization was used to assess the relationship of MFA and percent body fat with whole-body, lumbar spine, femoral neck, and forearm aBMD. Sex-stratified and age-stratified exploratory ana...
In all MR analyses, genetically predicted MFA was inversely associated with aBMD for the whole body (β = -0.053, p = 0.0002), lumbar spine (β = -0.075; p = 0.0001), femoral neck (β = -0.045; p = 0.008...
This study did not support the hypothesis that MFA protects against low aBMD. Instead, it showed that MFA may result in lower aBMD. Further research is needed to understand how MFA affects aBMD and ot...
A large number of observational studies showed that patients with psoriasis have a higher risk of cardiovascular disease (CVD), but most studies did not fully adjust for confounding factors, so it is ...
We used genetic instruments from the genome-wide association study (GWAS) of European descent for psoriasis to investigate its relationship with CVD. Inverse variance-weighted (IVW) MR analyses were u...
The fixed-effects IVW method indicated that genetic susceptibility to psoriasis was associated with a higher risk of heart failure (HF) [odds ratio (OR) = 1.04; 95% CI, 1.01-1.06, P = 2.72E-03], atria...
Our study provided evidence for a potential causal link between psoriasis and CVD. These findings partly suggest that early monitoring of cardiovascular risk in patients with psoriasis is intentional....
The immune microenvironment assumes a significant role in the pathogenesis of osteoarthritis (OA). However, the current biomarkers for the diagnosis and treatment of OA are not satisfactory. Our study...
The discovery dataset integrated the GSE89408 and GSE143514 datasets to identify biomarkers that were significantly associated with the OA immune microenvironment through multiple machine learning met...
Three signature genes (FCER1G, HLA-DMB, and HHLA-DPA1) associated with the OA immune microenvironment were identified as having good diagnostic performances, which can be used as biomarkers. MR result...
The present study identified the 3 potential immune-related biomarkers for OA, providing new perspectives for the prevention and treatment of OA. The MR study provides genetic support for the causal e...
There is little evidence on the genetic associations between life-course adiposity (including birth weight, childhood BMI, and adulthood BMI) and severe liver disease (SLD; including cirrhosis and liv...
Genetic variants were obtained from genome-wide association studies. Two-sample Mendelian randomization (MR) analyses were performed to assess the genetic associations of life-course adiposity with SL...
In observational analyses, genetic predispositions to childhood adiposity and adulthood adiposity were each associated with SLD. There was a U-shaped association between adulthood weight change and ri...
The current study provided genetic evidence on the associations between life-course adiposity and SLD....
The VITAL trial of vitamin D supplementation suggested a possible protective effect for autoimmune diseases but uncertainties remain. We investigated potential causal effects of vitamin D on composite...
We used data from 332,984 participants of the UK Biobank of whom 23,089 had at least one autoimmune disease defined using ICD code and/or self-report. Diseases were further considered in mechanistic s...
Genetically-predicted vitamin D was associated with lower risk of diseases in the autoinflammation group (OR 0.95 per 10 ng/ml increase in 25-hydroxycholecalciferol; 95%CI 0.91-0.99; p = 0.03) but not...
We found genetic evidence to support a causal link between 25-hydroxycholecalciferol concentrations and psoriasis and systemic lupus erythematosus. These results have implications for potential diseas...